Sei sulla pagina 1di 33

Testing / Sampling -- Drug Product

Manufacturing Process Validation

STRATEGIES TO WRITE EFFECTIVE


VALIDATION PROTOCOLS

Paul L. Pluta, PhD


Journal of Validation Technology
Journal of GXP Compliance
University of Illinois College of Pharmacy
Chicago, IL USA

OUTLINE

Protocols General
PV Guidance requirements
Process Validation Protocols
Equipment Qualification Protocols
Protocol Templates Key sections
and
d content
Protocol Problems
2

1
Testing / Sampling -- Drug Product
Manufacturing Process Validation

OBJECTIVES and APPROACH


Review FDA Process Validation Guidance (draft)
Specific FDA requirements
Consider FDA Guidance requirements in protocol
p p
preparation
Consider Corporate requirements / templates
Review PQ document group
Requirements of PV stages
Stage 1, Stage 2, Stage 3

Application to Qualification documents


Approval of validation documents
Templates for PQ documents provided
Protocol problems

Participation needed!
3

TERMINOLOGY: PROCESS VALIDATION

Process Validation Process Qualification

Qualification Qualification
E i
Equipment t #1 HVAC
Utilities
Equipment #2 Facilities
Computers
Equipment #3

Analytical methods validation


Cleaning process validation
Packaging process validation

Application to other process validation

2
Testing / Sampling -- Drug Product
Manufacturing Process Validation

FDA PROCESS VALIDATION GUIDANCE (DRAFT)

Definition: Collection and evaluation of data, from the


process design stage throughout production, which
establishes scientific evidence that a process is capable
of consistently delivering quality products.
products

Three stages of activities:


Stage 1 Process Design Development and scale-up activities
Stage 2 Process Qualification Reproducible manufacturing
Stage 3 Continued Process Verification Routine production

This document consistent with GHTF medical device process validation.

FDA PROCESS VALIDATION GUIDANCE (DRAFT)

Before commercial distribution to consumers, a


manufacturer should have gained a high degree of
assurance in the manufacturing process

Manufacturers should:
Understand the sources of variation
Detect the presence and degree of variation
Understand the impact of variation on the process and
product attributes
p
Control the variation in a manner commensurate with
risk to process and product

3
Testing / Sampling -- Drug Product
Manufacturing Process Validation

FDA PROCESS VALIDATION GUIDANCE (DRAFT)

Good project management and good archiving to capture


scientific knowledge.
Enhance accessibility of information later in lifecycle.
Integrated team approach: Process engineering, industrial
pharmacy, analytical chemistry, microbiology, statistics,
manufacturing, and quality assurance.

PROCESS DESIGN
(PROCESS UNDERSTANDING)
Define commercial-scale process
Define unit operations and process parameters
Identify and understand sources of variability
Identify critical process parameters
Studies to understand effects of scale
Establish mechanisms to control variability
Process Analytical Technology
Designed experiments
Lab scale and pilot scale experiments
Reference: McNally, Grace. GMP by the Sea, 8-07, 8-08

4
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PROCESS DESIGN (PROCESS UNDERSTANDING)


Objective
API and excipient pharmaceutics
Quality attributes
Risk analysis
Process parameters
Design of experiments
Design space
Normal operating range
In-process controls
Product development key inputs to design stage
Variability by different component lots, production operators,
environmental conditions, and measurement systems
Use risk analysis tools to screen variables
Establish a strategy for process control
9

QUALITY BY DESIGN (QbD)


1. Target product profile
2. Critical quality attributes
3. Critical process parameters
4. Design space
5. Input variable control strategy
6
6. Continuous improvement

Other considerations: PAT, Risk analysis

10

5
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PROCESS QUALIFICATION
(VALIDATION PERFORMANCE)
Confirmation at commercial scale of process design information
Qualification of equipment, utilities, facilities
Performance qualification
Conclusion that process consistently produces quality product.
Conformance batches
All support systems, documents, training, personnel, etc. in
place
Target / nominal operating parameters within design space
Additional testing
Decision to release
release process
process for routine commercial manufacturing

Reference: McNally, Grace. GMP by the Sea, 8-07, 8-08

11

PROCESS QUALIFICATION
Conformance Lots

Procedures
Validation plans
Protocols
Sampling
Testing
Results
Plan to maintain validation
alidation
ALL EQUIPMENT AND SUPPORTING SYSTEMS MUST
BE QUALIFIED.

12

6
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PERFORMANCE QUALIFICATION APPROACH


Higher level of sampling, testing, and scrutiny of process performance.

Protocol should address:


Operating parameters, processing limits, and raw material inputs
Data to be collected and how evaluated
Test to be performed and acceptance criteria
Sampling plan sampling points, number of samples, frequency
Statistical methods used
Statistical confidence levels
Provisions to address deviations and non-conformances
Facility, utility, and equipment qualification
Personnel training
Status of analytical method validation
Review and approval by appropriate departments and quality unit

NOTE DETAILS FROM PV GUIDANCE


13

PERFORMANCE QUALIFICATION APPROACH


The PQ lots should be manufacturer under normal conditions by
personnel expected to routinely perform each step of each unit
operation in the process. Normal operating conditions should cover
the utility systems (air handling and water purification), material,
personnel environment
environment, and manufacturing procedures.
procedures
PQ report:
Discuss all aspects of protocol
Summarize and analyze data as specified in protocol
Evaluate unexpected observations and additional data
Summarize and discuss nonconformances
Describe
D ib corrective
ti actions
ti or changes
h
Clear conclusions
Approval by appropriate departments and quality unit

NOTE DETAILS FROM PV GUIDANCE


14

7
Testing / Sampling -- Drug Product
Manufacturing Process Validation

CONTINUED PROCESS VERIFICATION


(VALIDATION MAINTENANCE)

Activities to assure process remains in validated state


Annual Product Review
T d and
Trend d assess d
data
t
Study OOS and OOT (Out of Trend) data
Timely monitoring of critical operating and performance
parameters.
Monitor product characteristics, personnel training, materials,
facilities, equipment, and SOP changes
Establish process history based on ongoing process
performance
Improve process
Improve control to detect and reduce variability
Change control; evaluate impact of change and test as necessary

Reference: McNally, Grace. GMP by the Sea, 8-29-07

15

CONTINUED PROCESS VERIFICATION


Monitoring
Statistical process control
Trend analysis
Change control
Continuous improvement
Revalidation
Management review

STATISTICIAN RECOMMENDED BY FDA

16

8
Testing / Sampling -- Drug Product
Manufacturing Process Validation

CONTINUED PROCESS VERIFICATION


ITEMS TO BE REVIEWED
Product and process data
Relevant process trends
Quality of incoming materials or components
In-process material
Finished products
Defect complaints
OOS findings
Deviations
Yield variations
Batch records
Incomingg raw material records
Adverse event reports
Production operator feedback
Operator errors also to measure quality of the training program

Above should help identify possible product / process improvements


17

EFFECTIVE PROTOCOLS
PROCESS VALIDATION

Stage 1: Product Design


Development information
Identification of CQA and CPP
Identification of sources of variation
Variation control plan
Stage 2: Process Qualification
Equipment qualification
Analytical method validation
Stage 3: Continued Process Verification
Post PQ plan
APR
Change control
18

9
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PRODUCT DESIGN INFORMATION


Technical reports from R&D
Pharmaceutics reports
Development reports (CQA, CPP impact protocols)
Technology transfer / Scale-up reports
Identification of sources of variation
Variation control plans
REPORTS STORED IN VALIDATION AREA OR BE READILY
AVAILABLE (within 30 minutes)

REPORTS SHOULD BE REVIEWED FOR CONSISTENCY


BETWEEN GROUPS

REPORTS SHOULD BE REFERENCED IN VALIDATION SPECIFIC


VALIDATION PLAN, PQ, AND RESULTS REPORT
19

PROCESS VALDIATION PROTOCOLS (PQ)


FDA GUIDLINE RECOMMENDATIONS
Higher level of sampling, testing, and scrutiny of process performance.

Protocol should address:


Operating
O ti parameters,
t processing
i limits,
li it andd raw material
t i l iinputs
t
Data to be collected and how evaluated
Test to be performed and acceptance criteria
Sampling plan sampling points, number of samples, frequency
Statistical methods used
Statistical confidence levels
Provisions to address deviations and non-conformances
Facility,
F ilit utility,
tilit and
d equipment
i t qualification
lifi ti
Personnel training
Status of analytical method validation

Review and approval by appropriate departments and quality unit

20

10
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION PHILOSOPHY
Validation is confirmation.
Acceptable results are expected.

Validation is not
Research
Final stage of development
Optimization
O ti i ti
Fine-tuning
Debugging
21

PROCESS VALDIATION DOCUMENTS


Corporate policy
Corporate templates use and supplement with new requirements
Validation Master Plan (VMP)
--------------------------------------------------

Validation Request
Validation Plan

Validation Protocol(s)
Engineering Study
Other requirements

Validation Results
Validation Report
--------------------------------------------------

22

11
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PROCESS VALIDATION DOCUMENTS


Written for the reader US vs. Europe
Objective: Understanding
Clarity much more important than brevity
Stand-alone document
Potential for review in 10+ years
Author / Management not available
Spelling and grammar correct
Need good writers Who writes protocols?
Simple sentences
Simple words
23

VALIDATION REQUEST
Objective of validation
Why needed?
Why acceptable? See Validation Plan
Impact of validation
Risk analysis

Approach to accomplish
Compliance to internal requirements and policies
Regulatory impact
Other systems or product impacted
Procedure changes or other document changes
Notifications to affected groups (internal, external, labs)

Above applicable to equipment and other qualification


24

12
Testing / Sampling -- Drug Product
Manufacturing Process Validation

TERMINOLOGY EXAMPLES

Validation request:
Process validation of Product A
S t
System: New
N product
d t validation
lid ti
Change impact: High impact. New product validation

Reason: New product to be manufactured at site

Justification: See Validation Plan

SIMPLE AND CLEAR

25

TERMINOLOGY EXAMPLES

Validation request:
Qualification of 150 cu. ft. blender
System: New equipment qualification
Change impact: High impact. New equipment and new
size at site

Reason: New equipment to increase manufacturing


efficiency and throughput

Justification: See Validation Plan

SIMPLE AND CLEAR


26

13
Testing / Sampling -- Drug Product
Manufacturing Process Validation

TERMINOLOGY EXAMPLES

Validation request:
Change air supply and return ductwork to coincide with Line 1 floor
space changes
System: HVAC system #3
Change impact: Medium impact. Change to direct product contact
support utility

Reason: Room configuration change to increase manufacturing


efficiency

Justification: See Validation Plan

SIMPLE AND CLEAR

27

VALIDATION PLAN

Introduction
Technical information
Validation strategy and testing
Validation documentation
List of required protocols, reports, procedures, etc.
References
Li t off reports
List t and
d scientific
i tifi references
f

Format development critical need model document

28

14
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION PLAN -- INTRODUCTION

INTRODUCTION
Overview describing validation / product / process /
equipment / etc.
Requirements to complete validation
Conformance to regulations and internal policy validation will
be completed
Impact of change to maintain the validated state
Impact on regulatory submission
Impact of change on procedures, drawings, other documents
Notifications to other areas internal and external
Notification to test labs and other areas impacted by validation

29

VALIDATION PLAN -- TECHNICAL INFORMATION


TECHNICAL INFORMATION
Basic product / process / equipment description
Formula
Process
Specifications
Include non-technical description information
Technical aspects of validation / qualification
Reference to technical reports from Design Stage or DQ
Total validation approach
Experimental studies
Past data (retrospective data)
V lid i protocols
Validation l
Other work
New procedures
Number of lots related to impact of change and risk

WRITTEN FOR THE READER


30

15
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION PLAN
VALIDATION STRATEGY AND TESTING
Prospective validation only
IQ / OQ / PQ -- general
Types of testing -- general
Regulatory specifications
Internal controls
Process tests
Tests and rationale general
Address changes based on risk analysis
Sampling and rationale general
Exceed routine QA testing based on impact and risk analysis
Data treatment general
Statistical data treatment
Acceptance criteria general

DETAILS OF ABOVE PROVIDED IN PROTOCOLS


31

VALIDATION PLAN
VALDIATION DOCUMENTATION
Doc # Title Date closed

01 Validation request

02 XXX Dryer Engineering Study

03 XXX Dryer Qualification

04 XXX Process Scale-up Engineering Study

05 XXX Process Validation

06 Update Validation Master Plan Product and


Equipment sections
07 XXX Project Summary Report

32

16
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION PLAN -- REFERENCES

R&D Reports
Published literature

Scientific and technical support to validation plan


Report copies in validation area

33

VALIDATION PROTOCOL
Objective of validation specific protocol
Validation description -- specific
System description (for equipment)
Validation approach
Testing and rationale -- specific
Sampling and rationale -- specific
Data treatment -- specific
Acceptance criteria specific
All testing must have acceptance criteria
Data sheets specific
Validation is confirmation
34

17
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION PROTOCOL
TESTING AND SAMPLING
Based on product specifications and testing
Exceed routine Q
QA testing
g based on impact
p and risk

Consider the following:


Product for seizures
Product for hypertension
New product
Change in compressing machine
Increase compressing machine speed
Change in granulation method
Change in batch size
35

VALIDATION PROTOCOL

FDA Powder Blends and Finished Dosage Units


Stratified Sampling and Assessment
Blend sampling.
sampling n = 1010, Indi
Individuals,
id als RSD
Tablets. 20 samples, n = 3-7 per location, mean,
range, RSD.

Application is possible approach for high risk


p
products
Supportive of USP Uniformity of Dosage Units on
composite / stratified samples
Product types: Potency and weight testing
36

18
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION SAMPLING
What is routine QA sampling?
Impact of change
No impact
Low impact
Medium impact
High impact

Risk analysis
y
High risk
Regular risk
Low risk
37

ENGINEERING STUDY
Conducted in advance of validation
No acceptance criteria
Trial
T i l run

Examples: Manufacturing process without


bulk drug (low dose API)
Process runs with placebo
Categories of Engineering Studies
Conduct Engineering Study concurrently with validation? -
- Not recommended
38

19
Testing / Sampling -- Drug Product
Manufacturing Process Validation

DATA SHEETS

Designed sheet with space for expected data


Data treatment specified
Signature and data of person supplying data
Highly recommended for Operators or persons not
familiar with sampling

Prevents missing data in complex protocols


Record sampling and / or testing

39

VALIDATION RESULTS
Data sheets
Data treatment
Results
Discussion
Results pass is not sufficient.
Validation statement:
Results indicate that ___ is validated.
Post-validation monitoring plan
40

20
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION REPORT

Recommended for complex projects


Recommended for multiple protocol projects
PRIMARY REPORT FOR AUDIT

Cut and Paste exercise from multiple


documents
Best approach to avoid inconsistency

41

VALIDATION REPORT FORMAT


Introduction
Key information from Validation Plan
Supporting information
Protocol #1 results
Protocol #2 results
Protocol #3 results
Protocol #n results
j
Project conclusions ((for Validation Plan))
Validation statement
Results indicate that ______ is validated.

42

21
Testing / Sampling -- Drug Product
Manufacturing Process Validation

EQUIPMENT QUALIFICATION
IQ, OQ, PQ
Same approach as with processes
Same philosophy
Same requirements
Same approval
Critical tests only
Non critical tests in FAC
Non-critical FAC, SAC
SAC, etc
etc.
Do as much as possible in commissioning
Difference from PV: Do tests only once

43

EQUIPMENT QUALIFICATION

IQ Installation Qualification
Function: Materials,, structure,, and maintenance
OQ Operational Qualification
Function: Operation
PQ Performance Qualification
Function: Operation with materials and / or
within other system components

44

22
Testing / Sampling -- Drug Product
Manufacturing Process Validation

VALIDATION DOCUMENT APPROVAL


Approval group must review documents
with p
perspective
p of an external auditor
Assure compliance with regulations
Assure acceptability of technical validation
and product quality
Assure acceptability of documentation
documentation.
Spelling and grammar

45

VALIDATION DOCUMENT APPROVAL


Technical validation
Scientific and technical principles
Consistent approach
Supports objective of validation
Supports routine manufacturing in type of testing and
sampling
Support routine manufacturing in duration of sampling
and testing
Results and discussion support data
Correct technical conclusions
Equipment testing support entire operating range used in
manufacturing
46

23
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PROTOCOL PROBLEMS
No plan
No basic explanation of validation
No statement of strategy and approach
No test rationale
No sampling rationale
How to treat data
No discussion of results
No acceptance criteria rationale
N validation
No lid ti statement
t t t
Poorly written

Written for the reader


47

PROTOCOL PROBLEMS
Protocol requires BME samples for potency.
Acceptance criteria: 95-105%
B = 95%
M = 100%
E = 105%
All results pass
p
Conclusion?

48

24
Testing / Sampling -- Drug Product
Manufacturing Process Validation

PROTOCOL PROBLEMS
There is no requirement for 3 lots.

Consider impact of change.


Consider product.
Consider risk.
What is post validation plan?

How many lots should be done?

49

SUPPORTING DOCUMENTS
PROCESS ANALYTICAL TECHNOLOGY (PAT)

Processes verified by PAT are not validated

All associated PAT equipment and analytical methods are


validated
Reference: FDA. PAT -- A Framework for Innovative Pharmaceutical
Development, Manufacturing, and Quality Assurance. September 2004

50

25
Testing / Sampling -- Drug Product
Manufacturing Process Validation

SUPPORTING DOCUMENTS
PROCESS ANALYTICAL TECHNOLOGY (PAT)

Process Understanding
All critical sources of variability are identified and explained.
Variabilityy is managed
g by y the pprocess
Product quality attributes can be accurately and reliably
predicted over the design space
Materials used
Process parameters
Manufacturing
Environmental
Other conditions

Reference: FDA. PAT -- A Framework for Innovative Pharmaceutical


Development, Manufacturing, and Quality Assurance. September 2004

WHEN PAT IS IN PLACE, WILL THERE BE ANY MORE VALIDATION?


51

SUMMARY
WHERE WE ARE -- CURRENT PRACTICE

R&D Validation Commercialization

52

26
Testing / Sampling -- Drug Product
Manufacturing Process Validation

SUMMARY -- VALIDATION CURRENT PRACTICE

Emphasis on repeatability (3x)


One-time effort
Documentation important
Last step in development
Hope we can pass validation
Required for product release to market
Key regulations:
1987 Process Validation Guidance
1990s Pharma Inspection Guidelines
1997 Medical Device Quality Systems Manual

53

SUMMARY -- WHERE WE ARE GOING


LIFECYCLE APPROACH TO PROCESS VALIDATION

Lifecycle approach:
Validation is never completed
Validation is always ongoing

Objectives:
Scientific and technical process
Demonstrate process works as intended
Process must remain in control

Reference: McNally, Grace E. GMP by the Sea, 8-07, 8-08

54

27
Testing / Sampling -- Drug Product
Manufacturing Process Validation

LIFECYCLE APPROACH TO PROCESS VALIDATION


Process Design
Studies to establish process
Identify critical process parameters
Identify sources of variation
Consider range of variation possible in processes
Process understanding g
Process Qualification
Equipment, facilities, and utilities
Confirm commercial process design
Validation performance
Continuous process verification
Monitor, collect information, assess
Maintenance, continuous verification, process improvement
Change control
Validation maintenance

The process of process validation.

Reference: McNally, Grace E. GMP by the Sea, 8-07, 8-08

55

SUMMARY
PROCESS VALIDATION HISTORY

1978
CGMP iincludes
l d V Validation
lid ti

1987
Development -- VALIDATION -- Control

2008
Lifecycle approach
Continuum of understanding validation maintenance
UNDERSTANDING -- VALIDATION -- MAINTENANCE

56

28
Testing / Sampling -- Drug Product
Manufacturing Process Validation

SUMMARY
VALIDATION -- FUTURE
Understanding Performance Maintenance

57

SUMMARY EFFECTIVE PROTOCOLS


Protocols consistent with validation guidelines and
expectations
Validation guidelines specify details
Validation is confirmation -- Acceptable results are
expected
Validation is not R&D, optimization, fine-tuning
New requirements
Scientific and technical basis
CQA and CPP
Sources of Variation
Variation Control Plan
Reference and retrieve R&D reports
58

29
Testing / Sampling -- Drug Product
Manufacturing Process Validation

SUMMARY
Protocol requirements
Specific guidance requirements
Strategy and approach
Impact of change
Risk analysis
Testing and sampling rationale
Acceptance criteria
Statistical data treatment
Data sheets
Post-validation monitoring plan
59

SUMMARY
Validation Results
Discussion of results
Validation statement
Summary report for multiple protocol
validation or complex products
Most important validation document
Simple sentences, simple words
Written for the reader

60

30
Testing / Sampling -- Drug Product
Manufacturing Process Validation

REFERENCES -- GENERAL
FDA. Guidance for industry. Process Validation: General Principles
and Practices. Draft Guidance, November 2008.
FDA. Guideline of General Principles of Process Validation. May,
1987.
FDA. Compliance Policy Guide 7132c.08. Section 490.100. Process
Validation Requirements for Drug Products and Active
Ph
Pharmaceutical
ti l Ingredients
I di t Subject
S bj t tto P
Pre-Market
M k t Approval.
A l
GHTF Study Group 3. Quality Management Systems -- Process
Validation Guidance. Edition 2, January 2004.
PQRI. Process Robustness. Pharmaceutical Engineering, Nov-Dec,
2006.
McNally, Grace E. Lifecycle Approach to Process Validation. DIA
Annual Meeting, 6-29-2005.
McNally, Grace E. Insights on Validation. GMP by the Sea,
Cambridge MD
Cambridge, MD. 8-29-2007
8 29 2007.
McNally, Grace E. Lifecycle Approach Process Validation. GMP by
the Sea, Cambridge, MD 8-26-08.
Famulare, Joseph. Benefits of a Pharmaceutical Quality System. PDA
/ FDA Joint Conference, Bethesda MD, 11-2-2007.
Health Canada. Validation Guidelines for Pharmaceutical Dosage
Forms (GUIDE-0029). 10-1-2004
61

REFERENCES PROCESS UNDERSTANDING

FDA. Guide to Inspections of Oral Solid Dosage Forms. Pre/Post


Approval Issues for Development and Validation. 1-94.
FDA. Guide to Inspections of Topical Drug Products. 7-94.
FDA. Guide to Inspections. Oral Solutions and Suspensions. 8-94
FDA PAT -- A F
FDA. Frameworkk ffor IInnovative
ti PhPharmaceutical
ti l
Development, Manufacturing, and Quality Assurance. 9-04.
ICH Q7. Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients. 11-10-00.
ICH Q8. Pharmaceutical Development. 11-10-05.
PQRI. Process Robustness. Pharmaceutical Engineering, 11-06.
Pharmaceutical Process Validation, 3rd edition. Drugs and the
Pharmaceutical Sciences, Volume 129. Marcel Dekker, New York,
NY 2003
NY, 2003.

62

31
Testing / Sampling -- Drug Product
Manufacturing Process Validation

REFERENCES PROCESS UNDERSTANDING

Product Quality Lifecycle Implementation (PQLI). www.ispe.org


Draft PQLI Summary Report update, 9-14-2007
Conformia. www.conformia.org
Ph
Pharmaceutical
ti l development
d l t Case
C Study:
St d ACE T Tablets,
bl t V 22.0.
0
Conformia CMC-IM Working Group, 3-13-2008.
Am Ende, Dave, et.al. API Quality by Design Example from the
Torcetrapib Manufacturing Process. J. Pharmaceutical Innovation 2,
71-86, 12-2007.
Stryczek, Karel, et.al. Capitalizing on Aggregate Data for Gaining
Process Understanding -- Effect of Raw Material, Environmental
anddP
Process C Conditions
diti on th
the di
dissolution
l ti R Rate
t off a S
Sustained
t i d
Release Product. J. Pharmaceutical Innovation 2, 6-17, 12-2007.
Somma, Russ. Development Knowledge Can Increase Manufacturing
Flexibility and Facilitate Quality by Design. J. Pharmaceutical
Innovation 2, 87-92, 12-2007.
63

REFERENCES PROCESS UNDERSTANDING


MacGregor, John F. et.al. A Framework for the Development of Design and
Control Space. J. Pharmaceutical Innovation 3, 15-22, 3-2008.
Cogdill, Robert P. et.al. Risk-based Quality by Design (QbD): A Taguchi
Perspective on the Assessment of Product Quality, and the Quantitative
Linkage of Drug Process Parameters and Clinical Performance. J.
Pharmaceutical Innovation 3, 23-29,
23 29, 3
3-2008.
2008.
Garcia, Thomas, et. al. PQLI Key Topics Criticality, Design Space, and
Control Strategy. J. Pharmaceutical Innovation 3, 60-68, 6-2008.
Nosal, Roger, et al. PQLI Definition of Criticality. J. Pharmaceutical Innovation
3, 69-78, 6-2008.
Lepore, John, et.al. PQLI Design Space J. Pharmaceutical Innovation 3, 79-
87, 6-2008.
Bolton, Ray, et.al. PQLI Engineering Controls and Automation Strategy. J.
Ph
Pharmaceutical
ti l Innovation
I ti 3,
3 88-94,
88 94 6-2008.
6 2008
Davis, Bruce, et.al. PQLI Control Strategy Models and Concepts. J.
Pharmaceutical Innovation 3, 95-104, 6-2008.
Seibert, Kevin D. et.al. The Use of Routine Process Capability for the
Deteriation of Process Parameter Criticality in Small-molecle SPI Synthesis.
J. Pharmaceutical Innovation 3,105-112, 6-2008.
64

32
Testing / Sampling -- Drug Product
Manufacturing Process Validation

REFERENCES VALIDATION PERFORMANCE


FDA. Guideline of General Principles of Process
Validation. 5-87.
FDA. Medical Device Quality Systems Manual. 1-97.
FDA. Guide to Inspections of Oral Solid Dosage Forms.
Pre/Post Approval Issues for Development and
Validation. 1-94.
FDA. Guide to Inspections of Topical Drug Products. July
1994. FDA. Guide to Inspections. Oral Solutions and
Suspensions. 8-94.
GHTF Study Group 3. Quality Management Systems --
Process Validation Guidance, Edition 2. 1-04.
ASTM E 2500-07.
2500 07 Standard Guide for Specification
Specification,
Design, and Verification of Pharmaceutical and
Biopharmaceutical Manufacturing Systems and
Equipment. 6-1-07

65

REFERENCES VALIDATION MAINTENANCE

FDA. Quality Systems Approach to Pharmaceutical CGMP


Regulations. September 9-06.
FDA. Pharmaceutical cGMPs for the 21st Centuryy -- A
Risk-Based Approach. 9-04.
ICH Q10. Pharmaceutical Quality System. 5-9-07.
GHTF Study Group 3. Quality Management Systems --
Process Validation Guidance, Edition 2. 1-04.
Joneckis, Chris, PhD. Implementing Quality Systems.
GMP by the Sea, Cambridge, MD. 8-29-06.

66

33

Potrebbero piacerti anche